HK Stock Market Move | ALPHAMAB-B(09966) surged more than 8%. The ASCO Annual Meeting in 2026 is approaching, with the company's research being selected for Late-Breaking Abstract (LBA).

ALPHAMAB-B (09966) rose more than 8% in intraday trading, closing up 7.06% at HK$10.01 with a trading volume of HK$23.1183 million. On the news front, Kangning Jer Bio-Pharmaceuticals recently announced that the Phase I clinical trial results of the global first TROP2/HER3 bispecific antibody-drug conjugate (ADC) JSKN016 for the treatment of HER2-negative locally advanced or metastatic breast cancer have been selected for presentation at the 2026 American Society of Clinical Oncology Annual Meeting (ASCO) in the form of a poster presentation. In addition, the significant results of the Phase III clinical trial of HER2 bispecific antibody ANIFUIDONGWAN (KN026) in combination with CSPC PHARMA's albumin-bound paclitaxel (HB1801) for neoadjuvant treatment of breast cancer have also been selected for presentation at the 2026 ASCO Annual Meeting as a "Latest Breakthrough Abstract" (LBA). The ASCO Annual Meeting will be held in Chicago, USA from May 29 to June 2, 2026.